Title:
ANTIBODY COMPOUNDS WITH REACTIVE CYSTEINE AND RELATED ANTIBODY DRUG CONJUGATES
Document Type and Number:
WIPO Patent Application WO/2023/212725
Kind Code:
A3
Abstract:
The present invention provides antibody compounds that contain a substitution of cysteine for the reactive lysine residue (lysine 93 by Kabat numbering) in the hydrophobic cleft (38C2_Cys). The invention also provides antibody drug conjugate compounds (ADCs) that contain cargo moieties that are site-specifically conjugated to the engineered cysteine residue in the 38C2_Cys variant antibody. Further provided in the invention are therapeutic applications of the compounds.
Inventors:
HWANG DOBEEN (US)
RADER CHRISTOPH (US)
RADER CHRISTOPH (US)
Application Number:
PCT/US2023/066399
Publication Date:
December 21, 2023
Filing Date:
April 28, 2023
Export Citation:
Assignee:
UNIV FLORIDA (US)
International Classes:
A61K47/68; A61P35/00; C07K16/32
Domestic Patent References:
| WO2006094269A2 | 2006-09-08 |
Foreign References:
| US20210340277A1 | 2021-11-04 |
Other References:
HWANG DOBEEN, NILCHAN NAPON, PARK HAJEUNG, ROY RAKTIM N., ROUSH WILLIAM R., RADER CHRISTOPH: "Sculpting a Uniquely Reactive Cysteine Residue for Site-Specific Antibody Conjugation", BIOCONJUGATE CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 33, no. 6, 15 June 2022 (2022-06-15), US , pages 1192 - 1200, XP093123123, ISSN: 1043-1802, DOI: 10.1021/acs.bioconjchem.2c00146
Attorney, Agent or Firm:
SATHER, Susan K. et al. (US)
Download PDF: